TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
about
Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosisHerpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growthCleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosisCD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cellsRole of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis throughCloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor familyA cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosisInvolvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)Parasporin, a human leukemic cell-recognizing parasporal protein of Bacillus thuringiensisIncreased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAILDifferential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamilyRespiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligandIrradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosisOnto better TRAILs for cancer treatmentMembrane trafficking of death receptors: implications on signallingDeath receptor-ligand systems in cancer, cell death, and inflammationApoptosis: role in myeloid cell developmentGetting TRAIL back on track for cancer therapyCrystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificityRole of nanotechnology and gene delivery systems in TRAIL-based therapiesMechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesIn chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areasPretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expressionTranscription initiation sites and promoter structure of the human TRAIL-R3 geneTumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cellsDeletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancerTRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signallingFollowing a TRAIL: update on a ligand and its five receptorsTrailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsVersatile assays for high throughput screening for activators or inhibitors of intracellular proteases and their cellular regulatorsMetformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer CellsGenetic variation in APOJ, LPL, and TNFRSF10B affects plasma fatty acid distribution in Alaskan Eskimos.Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectinEarly therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopyCoordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells.Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis.Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor.Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
P2860
Q21267232-1DC1FA9C-4711-46E7-90C7-0B69318FAE90Q22003914-40625658-1FD7-4CCB-A976-F440DF6749C9Q22010649-97B84BBE-2194-49D3-ADDE-9A7302372347Q24291469-7C4FFBFE-36B4-4A0E-8A00-AE04D3F62710Q24299363-690A39D9-9BFC-4223-BBCE-C55F1F3E09F8Q24315643-D0BD2F71-EDC9-403F-A985-ED8FE272737EQ24319367-8A5EDDB7-EAED-4690-885F-8AD0EB6BDE11Q24321282-4F9398A9-96E8-46C6-9A37-630DCF34210CQ24548861-5D062942-A7A9-4832-B900-DD659CE231E5Q24554360-A6646481-1B14-415F-97D2-B923B71174C9Q24654366-03CF7B2A-CF36-4BF3-A132-9E30AB54E176Q24683245-B6334879-7C3A-47C5-A9DE-C7DF1A490AAAQ24798681-B7824F7E-CCED-41CE-AC69-476B682E73D7Q26768160-95BE28E1-641E-4D46-9B4B-FD500F69AB75Q26852802-8EAF9293-6B0D-4BC8-BFD1-B7F1527098CEQ26865568-2AD05866-E8B1-4F0C-A254-F57F70F7FDBCQ27016041-E88992E5-7BC5-4BC0-A7DC-68DB31D24586Q27027460-8306BCB5-9490-4F60-9C72-DDC6684025A6Q27625357-CC20CBED-742F-4D8B-9255-C5E0FF2F0323Q28076798-4B1ABEA3-DFE6-40AA-ACB1-84EC9C2B7413Q28140698-0C4F0D42-7F88-4CBC-A306-7DF9A682C8E1Q28179380-8C2E0C93-D9DA-4E1A-BAE5-B19B1D8A7C79Q28192323-DAE3D203-E7FE-46AD-846A-6B1639133676Q28213507-59877423-2BCD-40B5-AC7C-9FC8BB6BBB87Q28215810-9C72D9C3-BB4D-40FA-B65B-7E4A1F83D229Q28245608-B4CACA54-4C17-4FE4-BBE9-F3ED514F08D9Q28267294-F90DAE43-D54F-48AB-A12F-5028A27C47DEQ28292767-A8862252-E6D9-4155-B46E-8F14488F4E4DQ28391040-00DDEB5B-8B81-469E-BF1F-BA690C6D2D6EQ28471677-D2F440BB-C991-4134-9F1D-BEF0266B71A8Q28547140-8FCF307D-7927-44BD-A1D5-2599FC703A41Q30494507-5F937C30-0AC2-49F2-A895-47AE03460873Q30523992-418EA6FD-1290-4053-BFB1-90D0B43FC17BQ30682911-7785C241-C90B-4DDC-9164-6819888DF816Q30896561-EB9EE464-FDCF-4E7E-8E85-1F834BD0B787Q31120918-9116EA0C-FB6F-4E37-9CD0-BB59445478E7Q31145220-33A708C0-C1A9-43EC-86E8-A7526C0521FBQ32051074-5E1F1A78-5440-43A2-8C40-73802E6749C0Q33387972-7DC75B96-C49B-438E-8752-D7B356B30413Q33410831-C386D409-A166-4BC5-A70D-AAA4C9CEA59C
P2860
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
@nl
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@ast
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en-gb
type
label
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
@nl
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@ast
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en-gb
prefLabel
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
@nl
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@ast
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en-gb
P2093
P2860
P921
P3181
P356
P1433
P1476
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
@en
P2093
Degli-Esposti MA
Gerhart MJ
Goodwin RG
Johnson RS
Schooley KA
P2860
P304
P3181
P356
10.1093/EMBOJ/16.17.5386
P407
P577
1997-09-01T00:00:00Z